

BIND Therapeutics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 09-Jul-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 9

[Return to Table of Contents](#)

BIND Therapeutics Inc

COMPANY OVERVIEW

| | |
|---------------------------------------|---|
| Company Name | BIND Therapeutics Inc |
| Parent Company Name | BIND Therapeutics Inc |
| Website | http://bindtherapeutics.com/ |
| Country | US |
| Number of Drugs in Active Development | 6 |
| Number of Inactive Drugs | 0 |
| Number of Patents as Owner | 15 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 4 |
| Key Indications | Cancer, Solid tumor, Non-small-cell lung cancer, Inflammatory disease, Prostate tumor, Cardiovascular disease, Breast tumor, Lung tumor, Asthma, Bladder cancer, Crohns disease, Dermatitis, Inflammatory bowel disease, Osteoarthritis, Ulcerative colitis, Uterine cervix tumor |
| Key Target-based Actions | Unspecified protein kinase inhibitor, Glutamate carboxypeptidase II inhibitor, Prostate specific antigen modulator, CD40 ligand, Epidermal growth factor ligand, Estrogen receptor agonist, GM-CSF ligand, Insulin-like growth factor ligand, Integrin alpha-V/beta-3 modulator, Interleukin-2 ligand, PDGF ligand, Somatostatin ligand, mTOR inhibitor |
| Key Technologies | Nanoparticle formulation, Small molecule therapeutic, Intravenous formulation, Nanoparticle formulation injectable, Controlled release formulation, Quick release formulation, Emulsion formulation, Formulation preservation, PEGylated formulation, Suspension |

COMPANY PROFILE

SUMMARY

BIND Therapeutics (previously BIND Biosciences Inc), founded in 2006, is a biopharmaceutical company specializing in the development of therapeutic targeted nanoparticles. In April 2013, BIND Biosciences changed its name to BIND Therapeutics.

R&D GRANTS

In October 2007, the National Institutes of Standards and Technology awarded BIND a 3-year \$2 million grant to further develop a high-throughput platform for its targeted nanoparticle technology.

Also in October 2007, the NCI awarded BIND a 6-month, \$0.15 million Phase I SBIR grant to develop a targeted therapy for hormone refractory prostate cancer.

FINANCIAL

In October 2011, BIND secured total proceeds of \$47.25 million through a \$22 million series D financing from RUSNANO and additional funding up to \$25.25 million from its investors.

In June 2010, the company secured \$12.4 million in a series C-1 financing.

In January 2010, the company secured \$11 million in a series C financing.

In November 2007, BIND was to raise \$16 million from a series B financing. The funding would be used to advance the company's preclinical pipeline to clinical trials.

EARLY R&D/TECHNOLOGY UPDATES

IND's Medicinal Nanoengineering platform aims to produce targeted nanoparticles with unprecedented control over drug properties to maximize trafficking to disease sites, leading to superior efficacy while minimizing toxicities.

[Return to Table of Contents](#)




By December 2007, BIND had been focusing on nanoparticles-targeting therapeutic for cancer, cardiovascular diseases and inflammatory diseases; in June 2010, the company planned to advance its second product into clinical development in 2011.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|------------------------|--------|----------|-------|
| Neoplasm | 4 | 0 | 4 |
| Respiratory disease | 1 | 0 | 1 |
| Cardiovascular disease | 1 | 0 | 1 |
| Inflammatory disease | 1 | 0 | 1 |

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 2 Clinical | 1 |
| Discovery | 5 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drug - Funding | 2 | 0 | 0 | 0 | 2 |
| Drug - Development/Commercialization License | 3 | 0 | 0 | 0 | 3 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|-----------------------|---------|-----|
| Neoplasm | 2 | 3 |
| Genitourinary disease | 1 | 1 |
| Respiratory disease | 1 | 1 |
| Andrology | 1 | 1 |

[Return to Table of Contents](#)

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 2 | 2 |
| Phase 1 | 0 | 1 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|---------------------------|----------|----------------|-------|
| Cardiovascular disease | 2 | 0 | 2 |
| Endocrine disease | 6 | 0 | 6 |
| Gastrointestinal disease | 3 | 0 | 3 |
| Genitourinary disease | 8 | 0 | 8 |
| Hematological disease | 2 | 0 | 2 |
| Andrology | 8 | 0 | 8 |
| Immune disorder | 3 | 0 | 3 |
| Musculoskeletal disease | 2 | 0 | 2 |
| Neoplasm | 10 | 0 | 10 |
| Ocular disease | 1 | 0 | 1 |
| Neurological disease | 4 | 0 | 4 |
| Respiratory disease | 4 | 0 | 4 |
| Infectious disease | 2 | 0 | 2 |
| Inflammatory disease | 2 | 0 | 2 |
| Gynecology and obstetrics | 7 | 0 | 7 |
| Dermatological disease | 2 | 0 | 2 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics

| | |
|-----------------------------|--|
| Drug Name | polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics |
| Key Synonyms | |
| Originator Company | BIND Therapeutics Inc |
| Active Companies | BIND Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Non-small-cell lung cancer, Cancer |
| Target-based Actions | Glutamate carboxypeptidase II inhibitor, Prostate specific antigen modulator |
| Other Actions | Cell cycle inhibitor, Microtubule inhibitor |
| Technologies | Nanoparticle formulation injectable, Intravenous formulation, Small molecule therapeutic |
| Last Change Date | 20-Jun-2013 |

targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics

| | |
|-----------------------------|---|
| Drug Name | targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics |
| Key Synonyms | |
| Originator Company | BIND Therapeutics Inc |
| Active Companies | BIND Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Inflammatory disease |
| Target-based Actions | |
| Other Actions | Unspecified drug target, Anti-inflammatory |
| Technologies | Nanoparticle formulation, Small molecule therapeutic |
| Last Change Date | 03-Apr-2013 |

[Return to Table of Contents](#)



targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics

| | |
|-----------------------------|---|
| Drug Name | targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics |
| Key Synonyms | |
| Originator Company | BIND Therapeutics Inc |
| Active Companies | BIND Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cardiovascular disease |
| Target-based Actions | |
| Other Actions | Unspecified drug target, Cardiovascular agent |
| Technologies | Nanoparticle formulation, Small molecule therapeutic |
| Last Change Date | 03-Apr-2013 |

molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics

| | |
|-----------------------------|---|
| Drug Name | molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics |
| Key Synonyms | |
| Originator Company | BIND Therapeutics Inc |
| Active Companies | BIND Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | |
| Other Actions | Anticancer |
| Technologies | Nanoparticle formulation, Small molecule therapeutic |
| Last Change Date | 08-Apr-2013 |

[Return to Table of Contents](#)



kinase inhibitor (Accurin nanomedicine, solid tumors), BIND Therapeutics/Amgen

| | |
|-----------------------------|--|
| Drug Name | kinase inhibitor (Accurin nanomedicine, solid tumors), BIND Therapeutics/Amgen |
| Key Synonyms | |
| Originator Company | BIND Therapeutics Inc |
| Active Companies | Amgen Inc, BIND Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Solid tumor |
| Target-based Actions | Unspecified protein kinase inhibitor |
| Other Actions | Anticancer protein kinase inhibitor |
| Technologies | Nanoparticle formulation, Small molecule therapeutic |
| Last Change Date | 05-Apr-2013 |

kinase inhibitor (Accurin nanomedicine, cancer), BIND Therapeutics/ AstraZeneca

| | |
|-----------------------------|---|
| Drug Name | kinase inhibitor (Accurin nanomedicine, cancer), BIND Therapeutics/ AstraZeneca |
| Key Synonyms | |
| Originator Company | BIND Therapeutics Inc |
| Active Companies | AstraZeneca plc, BIND Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | Unspecified protein kinase inhibitor |
| Other Actions | Anticancer protein kinase inhibitor |
| Technologies | Nanoparticle formulation, Small molecule therapeutic |
| Last Change Date | 23-Apr-2013 |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)